Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants
- 25 February 2005
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 23 (14), 1703-1708
- https://doi.org/10.1016/j.vaccine.2004.09.029
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Decrease of Invasive Pneumococcal Infections in Children Among 8 Children’s Hospitals in the United States After the Introduction of the 7-Valent Pneumococcal Conjugate VaccinePublished by American Academy of Pediatrics (AAP) ,2004
- Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate VaccineNew England Journal of Medicine, 2003
- The potential indirect effect of conjugate pneumococcal vaccinesVaccine, 2003
- Streptococcus pneumoniae-related illnesses in young children: secular trends and regional variationThe Pediatric Infectious Disease Journal, 2003
- Nasopharyngeal Carriage ofStreptococcus pneumoniaein Healthy Children: Implications for the Use of Heptavalent Pnemococcal Conjugate VaccineEmerging Infectious Diseases, 2002
- Six year multicenter surveillance of invasive pneumococcal infections in childrenThe Pediatric Infectious Disease Journal, 2002
- Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistanceThe Lancet Infectious Diseases, 2001
- Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis MediaNew England Journal of Medicine, 2001
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenThe Pediatric Infectious Disease Journal, 2000
- The Contribution of Specific Pneumococcal Serogroups to Different Disease Manifestations: Implications for Conjugate Vaccine Formulation and Use, Part IIClinical Infectious Diseases, 2000